Lupin gets U.S. FDA nod for Prucalopride Tablets for treatment of CIC in adults
Lupin Limited has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets, 1 mg and 2 mg. These tablets are the generic equivalent of Motegrity® Tablets by Takeda Pharmaceuticals U.S.A., Inc.
The approved product will be manufactured at Lupin's state-of-the-art facility in Goa, India.
Prucalopride Tablets are used for the treatment of chronic idiopathic constipation (CIC) in adults, a condition that causes difficult or infrequent bowel movements without a known cause. The drug works by stimulating bowel movements through selective serotonin 5-HT4 receptor agonism.
According to IQVIA MAT data for April 2025, Prucalopride Tablets (1 mg and 2 mg) had estimated annual sales of USD 184 million in the U.S., highlighting the strong market potential for Lupin's generic version.
This approval reinforces Lupin's position as a leading provider of high-quality, affordable generics in the U.S. pharmaceutical market.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
27 minutes ago
- Business Upturn
Food-Derived Longevity Supplement Primeadine® GF Launches at Erewhon
SHERIDAN, Wyo., June 26, 2025 (GLOBE NEWSWIRE) — Oxford Healthspan , a female-founded company dedicated to bringing food-derived longevity compounds to market, announces the launch of Primeadine® GF, its gluten-free spermidine supplement for healthy aging, at Erewhon, an independent, family-owned Certified B Corp and Certified Organic retailer with 10 locations across Southern California . Spermidine is a naturally occurring molecule that activates autophagy — a mechanism that mimics the effects of fasting by clearing out damaged cells and encouraging the regeneration of healthier ones. It also targets other key drivers of aging, including chronic inflammation, mitochondrial and stem cell dysfunction, and gut microbiome imbalances. As we age, the body's natural production of spermidine declines, making us more reliant on plant sources in our diet. Sourced from the longevity islands of Okinawa, Japan, Primeadine GF is a first-of-its-kind, gluten-free spermidine supplement sourced from a unique strain of Okinawan chlorella. It also contains two other autophagy-activating ingredients, nobiletin (from 'Shikuwasa' citrus lime peel) and curcumin (from turmeric). 'We're thrilled to bring Primeadine GF to Erewhon, where customers are deeply intentional about what they put in their bodies,' said Leslie Kenny, CEO and founder of Oxford Healthspan. 'This partnership is especially meaningful because both Oxford Healthspan and Erewhon are rooted in Japanese wellness traditions, from the macrobiotic movement that inspired Erewhon's founding to the Japan-sourced ingredients that power our supplements. We share a commitment to aging well through food-based approaches that honor both science and nature.' Primeadine GF delivers a range of science-backed benefits: Supports cellular renewal Promotes cognitive clarity, hormonal balance, and immune resilience Enhances skin, hair, and nail vitality from the inside out Backed by Oxford scientists and recommended by leading clinicians and nutritionists Tested for pesticides, heavy metals and toxins, and free from fillers and flow agents Primeadine GF is now available at all Erewhon locations across Southern California. Learn more about Primeadine GF at . About Oxford Healthspan Oxford Healthspan is a women-led, science-backed longevity supplement company dedicated to helping people age on their own terms by delivering premium, food-derived longevity supplements that harmonize Eastern wisdom with modern longevity science. With a mission to revolutionize healthy aging, Oxford Healthspan sources only the highest-quality ingredients from Japan to ensure purity, potency, and safety. Learn more at and follow @oxfordhealthspan on Instagram. About Erewhon Erewhon is an independent, family-owned Certified B Corp and Certified Organic Retailer with 10 locations across Southern California. Since 1968, Erewhon has been providing organic, ethically-sourced foods to the communities it serves. It's committed to sourcing healthy, nutrient-dense products, backing local growers and brands, and supporting the environment. Recognized for its uncompromising quality standards and customer service, Erewhon sustains a community centered in caring, curiosity, and positive change. For more information, visit MEDIA CONTACT:Lisa Lazarczyk, LAZ PR Tel: 617.838.7327 or [email protected]
Miami Herald
41 minutes ago
- Miami Herald
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset. "Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation," said Lisa Conte, Jaguar's Founder and CEO. "Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company." Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for Canalevia® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company. About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking StatementsCertain statements in this press release constitute "forward-looking statements." These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. CONTACT:hello@ SOURCE: Jaguar Health, Inc.
Yahoo
2 hours ago
- Yahoo
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset. "Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation," said Lisa Conte, Jaguar's Founder and CEO. "Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company." Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for Canalevia® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company. About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking StatementsCertain statements in this press release constitute "forward-looking statements." These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. CONTACT:hello@ SOURCE: Jaguar Health, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
